Myelo Therapeutics GmbH - Conventional chemotherapeutic agents for anticancer treatment typically target rapidly proliferating cells and do not discriminate between tumor cells and healthy cells.
Investors 1
Mentions in press and media 1
| Date | Title | Description |
| 08.01.2016 | Myelo Therapeutics Closes Series B Financing Round | Myelo Therapeutics GmbH, a Berlin and Dresden, Germany-based pharmaceutical company, closed a Series B financing round of undisclosed amount.
The round was co-led by IBB Beteiligungsgesellschaft mbH with its VC Fonds Technologie Berlin and ... |
Reviews 0
